The 548 brand-name drugs in the study included treatments for “rare diseases, cancer treatments, and common conditions like diabetes and heart disease,” according to the Boston Herald.
Drugs costing more than $150,000 a year “spiked from 9% in 2008-2013 all the way to 47% in 2020-2021,” the Herald reported.
The research findings arrived the same day the Federal Trade Commission announced an investigation into pharmacy benefit managers, an industry that’s been embroiled in controversy for years about its business practices.
The business practices for PBMs — which are responsible for valuing drug and treatment prices and are the step between insurers and payers — are “opaque,” the FTC said, prompting the investigation.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
